COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Decompensation Detection Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00583089
Recruitment Status : Completed
First Posted : December 31, 2007
Last Update Posted : February 6, 2017
Information provided by (Responsible Party):
Boston Scientific Corporation

Brief Summary:
To gather data and analyze decompensation events.

Condition or disease
Heart Failure

Layout table for study information
Study Type : Observational
Actual Enrollment : 699 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Decompensation Detection Study
Study Start Date : March 2006
Actual Primary Completion Date : March 2008
Actual Study Completion Date : March 2008

Algorithm Test Set
Algorithm Development Set

Primary Outcome Measures :
  1. Data collection and analysis. [ Time Frame: End of patient follow up. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Heart failure patients

Inclusion Criteria:

  • Patients implanted with an approved Guidant CRT-D HF device programmed to CRT therapy in VDD or DDD mode.
  • Patients prescribed to the LATITUDE(R) system configured for at least weekly device interrogations and symptoms reporting.
  • Patients willing to use the LATITUDE(R) enabled weight scale.

Exclusion Criteria:

  • Patients that require adaptive rate pacing (rate-responsive modes).
  • Patients that have received routinely scheduled intravenous inotropic therapy as part of their drug regimen within the past 90 days.
  • Both

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00583089

Sponsors and Collaborators
Boston Scientific Corporation
Layout table for investigator information
Principal Investigator: Gregory Ewald, M.D. Washington University School of Medicine
Principal Investigator: F. Roosevelt Gilliam, M.D. Cardiology Associates of Northeast Arkansas
Layout table for additonal information
Responsible Party: Boston Scientific Corporation Identifier: NCT00583089    
Other Study ID Numbers: DECODE
First Posted: December 31, 2007    Key Record Dates
Last Update Posted: February 6, 2017
Last Verified: February 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases